Publication Name	World Journal of Cardiology
Manuscript ID	29448
Country	United States

Received	2016-08-15 10:25
Peer-Review Started	2016-08-16 08:54
To Make the First Decision	2016-09-05 09:21
Return for Revision	2016-09-06 09:20
Revised	2016-10-31 00:00
Second Decision	2016-11-29 09:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-12-09 17:28
Articles in Press	2016-12-09 17:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-02-20 13:22
Publish the Manuscript Online	2017-02-23 11:56

ISSN	1949-8462 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Review
Article Title	PCSK9 inhibitors: A new era of lipid lowering therapy
Manuscript Source	Invited Manuscript
All Author List	Rahul Chaudhary, Jalaj Garg, Neeraj Shah and Andrew Sumner
Funding Agency and Grant Number
Corresponding Author	Jalaj Garg, MD, FESC, Division of Cardiology, Lehigh Valley Health Network, 1250 S Cedar Crest Blvd, Allentown, PA 18103, United States. garg.jalaj@yahoo.com
Key Words	Hyperlipidemia; Statins; Proprotein convertase subtilsin-kexin type 9
Core Tip	Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). However, there are limited options for patients who are either intolerant to statin therapy, develop CVD despite being on maximally tolerated statin therapy, or have severe hypercholesterolemia. The Food and Drug Administration has approved two novel medications for low-density lipoprotein (LDL)-cholesterol reduction in this patient population: Evolocumab and Alirocumab. These agents target and inactivate proprotein convertase subtilsin-kexin type 9 (PCSK9), a hepatic protease that attaches and internalizes LDL receptors into lysosomes hence promoting their destruction. By preventing LDL receptor destruction, LDL-C levels can be lowered 50%-60% above that achieved by statin therapy alone. PCSK9 inhibitors are an exciting agent for reducing LDL-C and have ushered in a new era of lipid lowering therapy.
Publish Date	2017-02-23 11:56
Citation	Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9(2): 76-91
URL	http://www.wjgnet.com/1949-8462/full/v9/i2/76.htm
DOI	http://dx.doi.org/10.4330/wjc.v9.i2.76

Full Article (PDF)	WJC-9-76.pdf
Full Article (Word)	WJC-9-76.doc
Manuscript File	29448-Review.doc
Answering Reviewers	29448-Answering reviewers.pdf
Audio Core Tip	29448-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	29448-Conflict-of-interest statement.pdf
Copyright License Agreement	29448-Copyright assignment.pdf
Peer-review Report	29448-Peer-review(s).pdf
Scientific Misconduct Check	29448-Scientific misconduct check.pdf
Scientific Editor Work List	29448-Scientific editor work list.pdf